SEC Form 4 · accession 0001133416-26-000059
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Khurram Jamil
Officer — Chief Medical Officer
Period of report
Jun 26, 2026
Accepted (ET)
Jun 30, 2026 · 7:23 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2026 | M | 2,037 | $2.20 | A | 2,037 | D | |
| Common StockF2 | Jun 26, 2026 | S | 2,037 | $5.00 | D | 0 | D | |
| Common Stock | Jun 26, 2026 | M | 2,533 | $2.50 | A | 2,533 | D | |
| Common StockF2 | Jun 26, 2026 | S | 2,533 | $5.00 | D | 0 | D | |
| Common Stock | Jun 29, 2026 | M | 47,467 | $2.50 | A | 47,467 | D | |
| Common StockF5 | Jun 29, 2026 | S | 47,467 | $5.04 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $2.20 | Jun 26, 2026 | M | 2,037 | D | Mar 11, 2025 | Mar 20, 2034 | Common Stock | 2,037 | 100,000 | D |
| Stock Option (right to buy)F4 | $2.50 | Jun 26, 2026 | M | 2,533 | D | Apr 30, 2025 | Aug 1, 2034 | Common Stock | 2,533 | 47,467 | D |
| Stock Option (right to buy)F4 | $2.50 | Jun 29, 2026 | M | 47,467 | D | Jul 31, 2025 | Aug 1, 2034 | Common Stock | 47,467 | 0 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
- F2The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027.
- F4The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025.
- F5The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.